## Highlights of This Issue 6953

### SPECIAL FEATURES

#### CCR Translations

6955  | **MAGE: The Spell Is Broken**  
Katayoun Rezvani  
*See article p. 7058*

#### CCR Drug Updates

6958  | **Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma**  
Evan J. Lipson and Charles G. Drake

#### Molecular Pathways

6963  | **Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells**  
Nicola Giuliani and Irma Airoldi

#### Perspective

6971  | **DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies**  
Graham A. Colditz and John Crowley

#### Reviews

6973  | **DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target**  
Shadia Jalal, Jennifer N. Earley, and John J. Turchi

6985  | **Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives**  
Jessica Godin-Ethier, Laila-Aicha Hanafi, Ciriaco A. Piccirillo, and Réjean Lapointe

---

### HUMAN CANCER BIOLOGY

#### Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase 1

Trisha R. Sippel, Jason White, Kamalika Nag, Vadim Tsvankin, Marcí Klæsens, B.K. Kleinschmidt-DeMasters, and Allen Waziri

#### Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome


#### Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma

David Z. Chang, Ying Ma, Baosai Ji, Huamin Wang, Defeng Deng, Yan Liu, James L. Abbruzzese, Yongjun Liu, Craig D. Logsdon, and Patrick Hwu

#### Two Distinct Routes to Oral Cancer Differing in Genome Instability and Risk for Cervical Node Metastasis


#### Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium

Hannah Barrow, Xiuli Guo, Hans H. Wandall, Johannes W. Pedersen, Bo Fu, Qicheng Zhao, Chen Chen, Jonathan M. Rhodes, and Lu-Gang Yu
CANCER THERAPY: PRECLINICAL

7047  Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy  
Yuhuan Li, Li-Xin Wang, Puiyi Pang, Zhihua Cui, Sandra Aung, Daniel Haley, Bernard A. Fox, Walter J. Urba, and Hong-Ming Hu

7058  Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4  
Conrad R. Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Andrea Sheehan, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Eslop, and Catherine M. Bollard

Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells  

Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies  

Synergistic Activity of Fenretinide and the Bcl-2 Family Protein Inhibitor ABT-737 against Human Neuroblastosoma  
Hua Fang, Theresa M. Harned, Ondrej Kalous, Vanessa Malagonado, Yves A. DeClerck, and C. Patrick Reynolds

Reduced miR-128 in Breast Tumor–Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5  
Yinghua Zhu, Fengyan Yu, Yu Jiao, Juan Feng, Wei Tang, Herui Yao, Chang Gong, Jianing Chen, Fengxi Su, Yan Zhang, and Erwei Song

Novel Phosphoinositide 3-kinase/mTOR Dual Inhibitor, SVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo  
Kwang-Yu Chang, Shan-Yin Tsai, Ching-Ming Wu, Chia-Jui Yen, Bin-Fay Chuang, and Jang-Yang Chang

IMAGING, DIAGNOSIS, PROGNOSIS

7139  Genetic Variation in Inflammatory Pathways Is Related to Colorectal Cancer Survival  
Anna E. Coghill, Polly A. Newcomb, Elizabeth M. Poole, Carolyn M. Hutler, Karen W. Makar, Dave Duggan, John D. Potter, and Cornelia M. Ulrich

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendrogial Brain Tumors: A Report from EORTC Study 26951  
Martin J. van den Bent, Lonneke A. Gravendeel, Thierry Gorlia, Johan M. Kros, Larisa Lapre, Pieter Wesseling, Johannes L. Teepen, Ahmed Idbaih, Marc Sanson, Peter A.E. Sillevis Smitt, and Pim J. French

CANCER THERAPY: CLINICAL

7156  Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors  
Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, and Jaap Verweij

A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer  
Malsa Mohabatsh, Kwong-Yok Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole, Caroline Jochems, Jaquelin Jones, Theresa Ferrara, Christopher B. Heery, Philip M. Aven, Seth M. Steinberg, Mary Pazdur, Myrna Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlim, and James L. Gulley
GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy

Guru Sonpavde, Timothy C. Thompson, Rajul K. Jain, Gustavo E. Ayala, Shinji Kurosaka, Kohsai Edamura, Ken-ichi Tabata, Chengzheng Ren, Alexei A. Goltsov, Martha P. Mims, Teresa G. Hayes, Michael M. Ittmann, Thomas M. Wheeler, Adrian Gee, Brian J. Miles, and Dov Kadmon

Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437

Monica M. Reinholz, Kathleen A. Kitzmann, Kathleen Tenner, David Hillman, Amylou C. Dueck, Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno-Aspitia, Vivek Roy, Betsy LaPlant, Jake B. Allred, Philip J. Stella, Wilma L. Lingle, and Edith A. Perez

Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer


ABOUT THE COVER

Human melanoma xenografts of UACC903 cells with activated BRAF mutation (V600E) were either untreated or treated with vehicle (DMSO) or the compounds riluzole, sorafenib, or riluzole with sorafenib. Upon termination of the experiment, the remaining tumors were excised and stained with activated caspase-3. This image is vehicle control. For details, see the article by Lee and colleagues on page 7080 of this issue.